We just got the first results from the National Cancer Institute's testing of one of our Ugi products (UC0204) for activity again tumor cell lines. It looks like there was no significant activity, which is not unexpected since these molecules were not selected based on any tumor related criteria.
In the future, we will be sending over compounds from the CombiUgi project that score higher on Rajarshi's algorithm to predict anti-tumor activity and things should get more interesting.
Tidak ada komentar:
Posting Komentar